Nanotechnology Approaches in Enhancing Bioavailability of Plant-Derived Antidiabetic Compounds for Obesity-Linked Diabetes

Kibibi Muthoni L.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Obesity-linked type 2 diabetes (T2D) arises from chronic nutrient excess, ectopic lipid deposition, and unresolved inflammation that together blunt insulin signaling and exhaust β-cell function. Plant-derived antidiabetic compounds, flavonoids (quercetin, kaempferol), phenolic acids (chlorogenic, caffeic), alkaloids (berberine), terpenoids (curcumin), and saponins (ginsenosides) modulate AMPK–mTOR, PI3K–AKT, PPARs, bile-acid–FXR/TGR5, and NF-κB/NLRP3 axes. Yet most exhibit poor aqueous solubility, chemical instability, extensive first-pass metabolism, efflux via P-glycoprotein, and rapid clearance, yielding low and variable systemic exposure. Nanotechnology offers a route to overcome these barriers by tailoring size, surface chemistry, and cargo architecture to improve dissolution, protect labile structures, promote intestinal permeation, and direct biodistribution to metabolic tissues. Lipidic carriers (liposomes, solid lipid nanoparticles, nanostructured lipid carriers, phytosomes), polymeric nanoparticles (PLGA, chitosan, PEG-PCL), cyclodextrin complexes, and hybrid or stimuli-responsive systems have achieved substantial gains in apparent solubility, oral bioavailability, and pharmacodynamic potency for lead phytochemicals in obese and diabetic models. Surface ligands that recognize hepatocyte asialoglycoprotein receptors, adipose vasculature motifs, or β-cell GLP-1 receptors enable tissue selectivity, while mucoadhesive and colon-targeted formulations reshape gut exposure to influence microbiome-host metabolism. This review synthesizes the pharmacokinetic obstacles facing plant bioactives, details design rules for nanocarriers that address dissolution–permeation–metabolism limits, and compares outcomes across platforms and payloads. We highlight considerations for scalability, safety, and regulatory acceptance, including critical quality attributes, in vitro–in vivo correlations, and human-relevant endpoints. Collectively, nanotechnology provides a pragmatic bridge from promising phytochemistry to translatable therapeutics capable of multi-target reprogramming in obesity-linked T2D without escalating systemic toxicity. Future studies should prioritize endotype-guided designs and combination payloads.

CITE AS: Kibibi Muthoni L. (2026). Nanotechnology Approaches in Enhancing Bioavailability of Plant-Derived Antidiabetic Compounds for Obesity-Linked Diabetes. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.111000